Lifecore Biomedical, Inc. (LFCR)
Lifecore Biomedical, Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Chaska, MN, US. The stock last traded at $4.86, up 0.67% on the session, giving a market capitalisation of $182.4M. On trailing twelve-month figures it carries a trailing P/E of -4.42, a net margin of -30.4%. Its beta of 1.08 implies it has historically moved more than the broad market.
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
Lifecore Biomedical, Inc. is most often compared with the following Healthcare names: